TIZIANA LIFE SCIENCES LTD (TLSA) Stock News
NASDAQ:TLSA - Nasdaq - BMG889121031 - Common Stock - Currency: USD
TLSA Latest News, Press Relases and Analysis
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences to Present at the Bio International Convention
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences to Present at the Bio International Convention
Uber Stock Ready to Ride Higher on Waymo Partnership
Uber stock may have just found a new way to come back into its growth phase, by seeking a new partnership with Alphabet's Waymo platform.
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
Tiziana Life Sciences Announces Purchase of Shares by Chairman
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Tiziana Life Sciences Ltd (NASDAQ:TLSA) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making […]
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week
New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3